Type 2 diabetes mellitus is a metabolic disorder characterized by hyperglycemia, insulin resistance in peripheral tissues, and altered insulin secretory capacity of pancreatic β-cells. Type 2 diabetes accounts for 90--95% of all cases of diabetes and is a major public health problem worldwide ([@b74-ehp0114-000641]). Established risks factors of type 2 diabetes include older age, obesity, physical inactivity, family history, and genetic polymorphisms. In addition, environmental toxicants, including arsenic, have been suggested to play an etiologic role in diabetes development ([@b34-ehp0114-000641]).

Arsenic is a recognized toxicant and carcinogen. Nonoccupational exposure occurs mainly through drinking water, affecting millions of people worldwide. Exposure to levels of arsenic in drinking water well above 100 ppb has been associated with an increased risk of type 2 diabetes in the high-arsenic areas of Taiwan and Bangladesh ([@b28-ehp0114-000641]; [@b49-ehp0114-000641]). The biological mechanisms for an association between chronic arsenic exposure and increased diabetes risk are not known \[[@b42-ehp0114-000641], [@b43-ehp0114-000641]; [@b60-ehp0114-000641]\].

Previous reviews of the role of arsenic in diabetes have questioned the quality of the evidence but were supportive of the possibility of an association \[[@b42-ehp0114-000641], [@b43-ehp0114-000641]; [@b41-ehp0114-000641]; [@b60-ehp0114-000641]; [@b61-ehp0114-000641], [@b62-ehp0114-000641]; [@b72-ehp0114-000641]\]. These reviews, however, did not use systematic review criteria and may be subject to biased selection of the evidence. Our objective was to perform a systematic review of the experimental and epidemiologic evidence on arsenic and type 2 diabetes. We examined experimental studies (*in vitro* or *in vivo*) to synthesize available information on plausible mechanisms for the effect of arsenic on glucose metabolism, as well as epidemiologic studies to synthesize the association of arsenic exposure with diabetes risk in humans.

Materials and Methods
=====================

### Search strategy and study selection.

We searched the Medline database (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>) and the TOXNET database \[consisting of TOXLINE, GENETOX, and DART/ETIC (Developmental and Reproductive Toxicology/Environmental Teratogen Information Center); <http://toxnet.nlm.nih.gov/>\] from 1966 through July 2005 using free text and the medical subject headings (MeSH) arsenic, arsenite, arsenate, arsenicals, diabetes, glucose, glycosylated hemoglobin, insulin, and mortality. In addition, we manually reviewed the reference lists from relevant original research and review articles.

For experimental studies, we identified *in vitro* or *in vivo* studies of the administration of arsenic or arsenic compounds, including inorganic arsenite (trivalent arsenic), inorganic arsenate (pentavalent arsenic), and others, and outcomes related to diabetes status or glucose and insulin metabolism. For epidemiologic studies, we identified studies assessing arsenic exposure through measures of environmental samples, biomarkers, or indirect measures (e.g., job titles reflecting occupational exposure or living in areas with known exposure via drinking water) and diabetes status or markers of glucose metabolism.

The exclusion criteria for experimental and epidemiologic studies were *a*) no original research (reviews, editorials, nonresearch letters); *b*) studies performed only on people with diabetes, including case reports; *c*) lack of outcomes related to diabetes or glucose metabolism; *d*) no data on arsenic exposure; *e*) experiments in nonmammalian cells, or noncellular experiments; *f*) animal studies administering a single dose of arsenic; and *g*) culture cell experiments using lewisite or oxophenylarsine. [Figure 1](#f1-ehp0114-000641){ref-type="fig"} summarizes the study selection process.

Two investigators (A.N.-A., R.A.S.) independently abstracted the articles that met the selection criteria. Discrepancies were resolved by consensus. We converted all arsenic concentrations to parts per million (ppm) or parts per billion (ppb), including concentrations from *in vitro* studies, which were usually reported in molar units of arsenic (1 μM of arsenic = 74.9 μg/L = 74.9 ppb).

### Statistical methods.

Measures of association in epidemiologic studies (odds ratios, prevalence ratios, standardized mortality ratios, relative risks, relative hazards, comparisons of means) and their SE values were abstracted or derived using data reported in the articles ([@b20-ehp0114-000641]). Within each study, we used the model adjusted for the most covariates. Adjustment did not substantially modify the conclusions of any individual study. For five studies, we used data available in the original articles to derive relative risk estimates. For one study ([@b27-ehp0114-000641]), because there were no cases among the unexposed, we added 0.5 to each cell to estimate the relative risk and the 95% confidence interval (CI). For [@b23-ehp0114-000641], we compared the proportion of subjects with glycosylated hemoglobin above 7% across occupational exposure categories. For [@b68-ehp0114-000641] and [@b52-ehp0114-000641], we used the linear discriminant function method to estimate relative risks from comparisons of means ([@b20-ehp0114-000641]). Finally, for [@b29-ehp0114-000641], we estimated the relative risk of diabetes mortality comparing the highest with the lowest category of exposure within the cohort from the published standardized mortality ratios.

We grouped the studies in three categories: studies in general populations exposed to high arsenic levels, corresponding to studies in Taiwan and Bangladesh with average levels in drinking water well above 100 ppb; studies in occupational populations exposed to high arsenic levels most commonly in ambient air; and studies in general populations exposed to low or moderate levels of arsenic in drinking water (\< 100 ppb), food, or ambient air. Because of substantial heterogeneity and methodologic limitations, we present a qualitative systematic review, and we used only meta-analysis techniques for studies from Taiwan and Bangladesh. For descriptive purposes, we report the range and the unweighted medians of the relative risk of diabetes comparing extreme categories of arsenic exposure in each study.

Results
=======

*In Vitro* Experimental Studies
-------------------------------

Nineteen *in vitro* studies published between 1965 and 2004 met our inclusion criteria ([Figure 1](#f1-ehp0114-000641){ref-type="fig"}, [Table 1](#t1-ehp0114-000641){ref-type="table"}). None of the experimental studies were conducted in human cell lines. Five experiments investigated the effect of arsenic on insulin signal transduction and gene expression. Three studies were performed in transfected mouse pancreatic β-cells, where exposure to high arsenite concentrations was similar to high glucose in stimulating insulin upstream factor 1 (IUF-1) ([@b38-ehp0114-000641]) and in stimulating the translocation of IUF-1 from the cytoplasm to the nucleus ([@b16-ehp0114-000641]; [@b37-ehp0114-000641]). IUF-1, also called homeodomain transcription factor PDX1, is a transcription factor that binds to the human insulin gene promoter and increases insulin messenger RNA levels in response to glucose. The effect of high glucose or arsenite was prevented by SB 203580, a specific inhibitor of stress-activated protein kinase-2 (SAPK2)/p38, whereas the effect of high glucose but not of arsenite was prevented by substances that specifically inactivate phosphatidylinositol-3 kinase (wortmannin and LY294002). Two other studies ([@b53-ehp0114-000641]; [@b71-ehp0114-000641]) investigated the role of arsenite in adipocyte differentiation and peroxisome proliferative-activated receptor γ (PPARγ) expression. PPARγ is a transcription factor that regulates key gene expression for insulin sensitivity. These two experiments used different concentrations and lengths of exposure and produced opposite results. In the study by [@b53-ehp0114-000641], the incubation of 3T3-F442A preadipocytes with 1.7 and 3 ppb (0.25 and 0.5 μM) arsenite for 3 days induced the expression of PPARγ and CCAAT/enhancer binding protein. In study by [@b71-ehp0114-000641], the incubation of C3H 101T1/2 cells with 450 ppb (6 μM) arsenite for 2 months prevented adipocyte differentiation through the inhibition of the PPARγ. Arsenite also inhibited the differentiating effect induced by pioglitazone, a PPARγ agonist used to reduce insulin resistance.

The rest of the *in vitro* studies assessed the effect of arsenic on glucose uptake, typically using very high concentrations of arsenite as general inducers of cellular stress. Ten studies measured basal glucose uptake (in the absence of insulin) in cell lines exposed to arsenite or other compounds ([Table 1](#t1-ehp0114-000641){ref-type="table"}, [Figure 2](#f2-ehp0114-000641){ref-type="fig"}). Four of the studies also exposed the cells simultaneously to insulin and arsenite ([Table 2](#t2-ehp0114-000641){ref-type="table"}). Compared with insulin alone, simultaneous exposure to insulin and arsenite decreased glucose uptake in insulin-sensitive cells ([@b7-ehp0114-000641]; [@b65-ehp0114-000641]). One of the studies ([@b65-ehp0114-000641]) measured basal and insulin-stimulated glucose uptake in cells exposed to arsenate and to methylated arsenic compounds. Methylarsine oxide (MAs^III^O) inhibited insulin-stimulated glucose uptake at the concentration of 75 ppb after 4- or 24-hr exposure ([@b65-ehp0114-000641]). For arsenite, because the concentrations used in glucose uptake studies were extremely high, their relevance to diabetes development in humans is questionable.

Overall, *in vitro* studies provided limited insight into potential mechanisms that may explain an etiologic role of arsenic on diabetes.

*In Vivo* Experimental Studies
------------------------------

Ten experimental studies in mice, rats, goats, and guinea pigs published between 1979 and 2004 met our inclusion criteria ([Figure 1](#f1-ehp0114-000641){ref-type="fig"}, [Table 3](#t3-ehp0114-000641){ref-type="table"}). Arsenite was evaluated in 6 studies ([@b8-ehp0114-000641]; [@b13-ehp0114-000641]; [@b19-ehp0114-000641]; [@b44-ehp0114-000641], [@b45-ehp0114-000641], [@b46-ehp0114-000641]), and arsenate in 2 studies ([@b1-ehp0114-000641]; [@b21-ehp0114-000641]). Other compounds were methanearsonate ([@b24-ehp0114-000641]) and monomethylarsenic ([@b3-ehp0114-000641]). Six studies administered arsenic in water or food for lengths of time ranging from 4 weeks to 2 years, and 5 studies involved intraperitoneal exposure to arsenic for 5--30 days. The doses of arsenic were high or very high in most studies, with a lowest dose of 5.55 ppm arsenite ([@b44-ehp0114-000641]) and 0.025 ppm arsenate ([@b21-ehp0114-000641]).

Although all studies measured glucose levels in blood, plasma, or serum, only one study provided information on potential mechanisms ([@b13-ehp0114-000641]). In this study, the oral administration of arsenite did not affect insulin levels *in vivo*. However, a glucose stimulus applied *ex vivo* produced greater insulin release from the isolated pancreas cells of rats treated with arsenite *in vivo* compared with the insulin release from isolated pancreas cells of control rats.

Epidemiologic Studies
---------------------

### Study characteristics.

Nineteen epidemiologic studies met our inclusion criteria ([Figure 1](#f1-ehp0114-000641){ref-type="fig"}, [Table 4](#t4-ehp0114-000641){ref-type="table"}). Three studies were published between 1980 and 1984 ([@b17-ehp0114-000641]; [@b36-ehp0114-000641]; [@b68-ehp0114-000641]), and the other 15 were reported between 1994 and 2004. Only 2 studies used a prospective cohort design ([@b29-ehp0114-000641]; [@b66-ehp0114-000641]). The rest used cross-sectional, case--control, or retrospective cohort designs. Two studies used the WHO diabetes definition based on oral glucose tolerance tests and/or self-reported medication to define diabetes, whereas the other studies used death certificates, medical or insurance records, urine tests for glucosuria, self-reported diabetes symptoms such as polyuria confirmed by two positive urine tests and a positive oral glucose tolerance test, glycosylated hemoglobin, or self-reported diagnosis. Two studies did not specify the diagnostic criteria. The number of diabetes cases ranged from 2 ([@b36-ehp0114-000641]) to 27,543 ([@b66-ehp0114-000641]), but most studies had fewer than 100 cases. Studies in general populations included adult men and women, whereas occupational studies included mostly men.

There were substantial differences in arsenic exposure ascertainment. Most studies in general populations assessed exposure indirectly, using measurements of total arsenic levels in community drinking water sources. Two studies from Taiwan ([@b28-ehp0114-000641]; [@b61-ehp0114-000641]), one from Bangladesh ([@b50-ehp0114-000641]), and one from the United States ([@b29-ehp0114-000641]) estimated a cumulative arsenic exposure index (ppm-year) by multiplying the number of years that individuals lived in a specific village/area by the average arsenic level in drinking water in that village/area (usually, in each area, several measurements were performed once in time). Other studies in Taiwan and Bangladesh assigned exposure on the basis of residence in an area determined to be endemic for arseniasis ([@b49-ehp0114-000641]; [@b59-ehp0114-000641]; [@b66-ehp0114-000641]). None of the studies from Taiwan or Bangladesh obtained individual measures of arsenic exposure either from household tap water measures or more directly by using biomarkers of exposure. None of these studies assessed potential sources of exposure other than drinking water. In occupational studies, exposure was based on job title or on estimated arsenic levels in air for different job categories as assessed by a safety engineer ([@b48-ehp0114-000641]). One study in an occupationally exposed area assessed arsenic exposure based on years of residence within 4 km of a copper smelter during childhood ([@b58-ehp0114-000641]). Some occupational studies ([@b17-ehp0114-000641]; [@b23-ehp0114-000641]; [@b27-ehp0114-000641]; [@b35-ehp0114-000641]) also measured arsenic in urine or air to confirm exposure, but this information was not linked to diabetes in the analyses. Only two studies used biomarkers of exposure: [@b68-ehp0114-000641] measured total arsenic in plasma, and [@b52-ehp0114-000641] measured total arsenic in urine, without speciation of inorganic and methylated compounds.

### Quality assessment.

In the epidemiologic studies we abstracted information to evaluate study quality, adapting the criteria proposed for observational studies by [@b33-ehp0114-000641]. As shown in [Table 5](#t5-ehp0114-000641){ref-type="table"}, most studies failed to fulfill important quality criteria such as individual measures of arsenic exposure using biomarkers, standard criteria to diagnose diabetes, or information on established risk factors for diabetes.

### Relative risk estimates.

The relative risk estimates comparing the highest with the lowest arsenic exposure categories are shown in [Table 4](#t4-ehp0114-000641){ref-type="table"}. Studies in Taiwan and Bangladesh consistently identified an increased risk of diabetes with increased arsenic exposure, with relative risks ranging from 1.46 to 10.1 (median, 2.40) and with a pooled relative risk estimate using and inverse variance weighted random-effects model of 2.52 (95% CI, 1.69--3.75; *p* heterogeneity \< 0.001). Occupational studies were small and showed no consistent pattern, with relative risks ranging from 0.34 to 9.61 (median, 1.40). We identified only 4 studies in general populations from countries with low or moderate arsenic exposure. These studies were small and did not show an increased risk of diabetes with increasing arsenic levels (relative risks ranged from 0.65 to 1.09; median, 0.95).

Five studies provided information on the dose response in diabetes risk by cumulative arsenic exposure in drinking water ([Figure 3](#f3-ehp0114-000641){ref-type="fig"}). Diabetes risk tended to increase with increasing cumulative exposure in studies from Taiwan ([@b28-ehp0114-000641]; [@b61-ehp0114-000641]) and Bangladesh ([@b50-ehp0114-000641]). No trend was observed in the U.S. studies ([@b29-ehp0114-000641]; [@b78-ehp0114-000641]).

Discussion
==========

### Summary of findings.

The evidence on the association of arsenic exposure with diabetes risk summarized in this systematic review is inconclusive. Evidence from *in vitro* studies suggests that arsenic interferes with signal transduction and transcription factors that are related to insulin pathways such as IUF-1 in pancreatic cells or PPARγ in preadipocytes. *In vitro* glucose uptake experiments and *in vivo* studies did not provide evidence on potential mechanisms that may explain a diabetogenic effect of arsenic. In general, experimental studies were limited by the use of arsenic concentrations that were much higher than those relevant to human exposure. For example, the current U.S. Environmental Protection Agency recommended standard for arsenic in drinking water is 10 ppb. The lowest concentration of arsenite used in studies of cultured cells investigating glucose uptake was 750 ppb ([@b7-ehp0114-000641]), and the lowest concentration of arsenite in animal studies was 5,550 ppb ([@b44-ehp0114-000641], [@b45-ehp0114-000641]).

In epidemiologic studies, the association between arsenic exposure and diabetes across different populations and different sources of exposure was inconsistent. In populations exposed to high arsenic levels via drinking water in Taiwan and Bangladesh, diabetes risk was consistently increased. In occupational settings, diabetes mortality was increased in some studies and decreased in others. Finally, no association with diabetes was observed in four studies of general populations outside of Taiwan or Bangladesh. Overall, the quality of the epidemiologic evidence was limited by methodologic problems, particularly in assessing arsenic exposure and diabetes outcomes.

### Mechanisms for arsenic-related diabetes.

Acute arsenite toxicity, including its effects on glucose metabolism, is generally attributed to its reactivity toward thiol (SH) groups ([@b2-ehp0114-000641]; [@b42-ehp0114-000641]). During acute poisoning, arsenite inhibits pyruvate and α-ketoglutarate dehydrogenases ([@b2-ehp0114-000641]), essential enzymes for gluconeogenesis and glucolysis. The interference of arsenic with pyruvic acid metabolism was described by Krebs in the early 1930s ([@b26-ehp0114-000641]). Arsenate, on the other hand, can replace phosphate in energy transfer pathways of phosphorylation and also uncouples oxidative phosphorylation ([@b25-ehp0114-000641]). However, these toxic effects of acute arsenic exposure are unlikely to occur as a result of chronic exposure to environmentally relevant doses ([@b60-ehp0114-000641]).

The influence of arsenic on the expression of gene transcription factors may be related to diabetes risk. However, the effects of arsenite on IUF-1 and PPARγ were contradictory in terms of diabetes development. The differential effects may reflect a complex dose--response pattern for arsenic or differences in length of exposure to arsenic across studies. Further studies with wide ranges and durations of arsenic exposure are needed to investigate the effect of arsenic on these and other insulin-related events at the cellular and molecular levels. For instance, interference with the glucocorticoid receptor is another potential mechanism for arsenic-related diabetes that deserves further investigation. Arsenic shows a complex dose--response effect on glucocorticoid receptor mediated transcription ([@b9-ehp0114-000641]), with a stimulatory effect at very low concentrations (6--120 ppb) and an inhibitory effect at doses greater than 120 ppb. The glucocorticoid receptor is a member of the steroid receptor superfamily that among other metabolic processes regulates gluconeogenesis. Reduction of glucocorticoid receptor expression in hepatic and adipose tissue has been shown to improve hyperglycemia in diabetic rodents ([@b70-ehp0114-000641]).

Experimental studies on glucose uptake showed that arsenite increases uptake independently of the earlier steps of the insulin transduction pathway, although when co-administered with insulin, arsenite inhibited insulin-stimulated glucose uptake in 3T3-L1 adipocytes. The purpose of most of these studies was to investigate the role of stress in glucose uptake, which is unrelated to the possibility that arsenic could affect diabetes risk. Under these designs, cultured cells were exposed to high arsenic levels for a few hours, whereas humans are chronically exposed to lower concentrations. Only one study investigated methylated arsenical compounds and their interference in insulin signaling in adipocytes ([@b65-ehp0114-000641]). For these reasons, the relevance of *in vitro* glucose uptake findings to diabetes etiology is uncertain.

Arsenic could influence diabetes development by other mechanisms, including oxidative stress, inflammation, or apoptosis, nonspecific mechanisms that have been implicated in the pathogenesis of type 2 diabetes. Arsenic exposure can enhance the production of reactive oxygen species ([@b4-ehp0114-000641]; [@b12-ehp0114-000641]; [@b60-ehp0114-000641]; [@b67-ehp0114-000641]), interfere with the activity of key antioxidant enzymes such as glutathione reductase, glutathione *S*-transferase, glutathione peroxidase, and glucose 6-phosphate dehydrogenase ([@b39-ehp0114-000641]; [@b54-ehp0114-000641]), and induce lipid peroxidation ([@b54-ehp0114-000641]). In individuals from Taiwan, increasing blood levels of arsenic correlated with increasing levels of reactive oxygen species and with decreasing levels of antioxidant capacity in plasma ([@b76-ehp0114-000641]). Arsenic may also up-regulate interleukin-6 and other inflammatory cytokines ([@b75-ehp0114-000641]), and it may induce the release of tumor necrosis factor-α from mononuclear cells ([@b77-ehp0114-000641]). Finally, arsenic is well known for inducing apoptosis in multiple cell lines ([@b63-ehp0114-000641]). Future research should evaluate whether these mechanisms mediate the role of arsenic in diabetes development.

The *in vivo* experimental studies were mostly uninformative. The diversity of species studied probably reflects that there are no good animal models to study the effects of arsenic on diabetes development. Indeed, the classification of arsenic as a human carcinogen, although recently supported by animal models ([@b64-ehp0114-000641]), was for a long time based on human data. Progress in the study of the role of arsenic in diabetes requires the identification of appropriate animal models.

### Arsenic and diabetes in human studies.

Suggestive evidence links chronic exposure to high arsenic levels in drinking water with increased diabetes risk in Taiwan and Bangladesh. Methodologic problems, however, limit the causal interpretation of this association. The use of average drinking water and the lack of individual measures of arsenic make it possible to underestimate exposure due to between-subject variability in water consumption and to other sources of arsenic exposure in these areas, such as contaminated food and cooking water. On the other hand, because arsenic exposure was assessed at the village level and diabetes diagnosis was often not performed according to standard procedures, this ecologic association could reflect the uncertain comparability of exposure groups in terms of socioeconomic development, access to care, study selection factors and other diabetes risk factors. The use of urine tests and of administrative data to identify diabetes makes it likely that only severe or symptomatic cases were identified, and it is uncertain whether the procedures and frequency for diabetes testing were similar across areas with different arsenic exposure. In addition, the use of administrative data can be affected by surveillance and diagnostic biases. For example in Taiwan, arsenic-related health problems in the endemic areas are well known, hence, subjects in these areas may have received different medical care, including different diagnostic services, compared with subjects in areas with lower arsenic levels.

It is also possible that the findings from Taiwan and Bangladesh may not be generalizable to other populations. Some reasons for this include variations in the distribution of polymorphisms in genes involved in arsenic metabolism or response ([@b32-ehp0114-000641]), differences in arsenic species to which populations were exposed ([@b11-ehp0114-000641]), other co-exposures ([@b11-ehp0114-000641]), and dietary deficiencies that may interact with arsenic. For example, selenium and zinc levels in Taiwan and Bangladesh are among the lowest worldwide ([@b31-ehp0114-000641]), and poor dietary selenium has been suggested as an underlying factor for arsenic and cancer in Bangladesh and West Bengal in India ([@b56-ehp0114-000641]). In guinea pigs, selenium and arsenic counteract each other in glucose metabolism ([@b14-ehp0114-000641]), and the joint effect of high arsenic and low selenium could play a role in diabetes development. Exposure to arsenic, selenium, other nutrients, and other diabetes risk factors were not measured in epidemiologic studies.

We found no reports of diabetes in populations known to be exposed to high levels of arsenic in drinking water in Chile and Argentina. This lack of information on diabetes could reflect a lack of research, but it has also been suggested to be related to publication bias ([@b34-ehp0114-000641]).

The evidence from general populations outside of Taiwan or Bangladesh was inconclusive because of the small number of cases, limitations in study design, and misclassification of diabetes status. Occupational studies, on the other hand, could not be interpreted in favor or against an association because of uncertain comparability of study participants with the general population used as reference, limitations in exposure assessment, lack of information on concomitant exposures, lack of information on major diabetes risk factors, and the possibility of a healthy worker survivor effect.

An important conclusion we derived from the epidemiologic review is the limited quality of the evidence base. This finding is consistent with previous reviews, including those by U.S. and international panels ([@b42-ehp0114-000641], [@b43-ehp0114-000641]; [@b41-ehp0114-000641]; [@b72-ehp0114-000641]). These panels determined that the available evidence on arsenic and diabetes suffered from uncertainties in study design and exposure assessment. Our review further refines these reports and identifies the lack of biomarker data and the lack of standard criteria for diabetes assessment as major limitations of the evidence base. Current uncertainties in the role of arsenic in diabetes development could be reduced by conducting carefully planned epidemiologic studies in populations exposed to a wide range of arsenic levels. Future studies should *a*) measure appropriate arsenic biomarkers that integrate all sources of exposure (e.g., urine or toenails); *b*) carefully collect information on current and past sources of arsenic exposure and on potential confounders and modifiers, including known determinants of diabetes development; *c*) and prospectively ascertain diabetes using standard definitions.

Conclusion
==========

The possibility of an association between chronic arsenic exposure and diabetes has implications for research and public health. Millions of people are exposed worldwide to moderate or high levels of arsenic in drinking water. Because diabetes is also a major public health problem, the public health consequences of a causal association could be serious. Methodologic problems limit the causal interpretation of the moderately strong association between high arsenic exposure and diabetes in Taiwan and Bangladesh. Overall, the experimental and epidemiologic evidence is at present insufficient and inadequate to establish causality. Experimental studies that use arsenic concentrations relevant to human exposures, and high-quality prospective epidemiologic studies that use appropriate methods for exposure assessment as well as rigorous criteria for outcome definitions should be research priorities.

C[orrection]{.smallcaps}
========================

[Table 1](#t1-ehp0114-000641){ref-type="table"} has been modified from the original manuscript published online. The table now includes information on the 24-hr study by [@b65-ehp0114-000641].
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![Ratio of basal glucose uptake in peripheral cell lines comparing arsenite versus control. Lines represent the dose response for each independent study. Single points represent the effect for studies using a single dose (1 ppm = 13.35 μM; 0.75 ppm = 10 μM).](ehp0114-000641f2){#f2-ehp0114-000641}

![Risk of diabetes by cumulative arsenic exposure in drinking water in epidemiologic studies. Black lines represent the dose response for studies in Taiwan and Bangladesh compared with the baseline category of exposure. Gray lines represent the dose response in studies in the United States. Cumulative exposure: ∑ arsenic levels in drinking water*~i~* × time of exposure***i*** (*i* indicates specific village). For example, a cumulative exposure of 1 ppm-year is reached after 10 years of residence in a village with an arsenic concentration in drinking water of 0.1 ppm. In the study by [@b78-ehp0114-000641], we assumed 20 years of exposure for all study subjects.](ehp0114-000641f3){#f3-ehp0114-000641}

###### 

*In vitro* studies of arsenic exposure and glucose metabolism outcomes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                    Type of cell/tissue           Compound     Dose (ppm)         Incubation   Outcomes and results (compared with controls)
  ----------------------------------------- ----------------------------- ------------ ------------------ ------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Signal transduction and gene expression                                                                              

   [@b38-ehp0114-000641]                    Pancreatic β-cells            Arsenite     37.5               0.33 hr      ↑ IUF-1 dependent gene expression\
                                                                                                                       PI-3 kinase independent; SAPK2/p38 involved

   [@b37-ehp0114-000641]                    Pancreatic β -cells           Arsenite     75                 0.5 hr       ↑ IUF-1 translocation from cytoplasm to nucleus\
                                                                                                                       PI-3 kinase independent; SAPK2/p38 involved

   [@b16-ehp0114-000641]                    Pancreatic β-cells            Arsenite     75                 0.5 hr       ↑ IUF-1 translocation from cytoplasm to nucleus\
                                                                                                                       PI-3 kinase independent; SAPK2/p38 involved

   [@b71-ehp0114-000641]                    C3H 10T1/2 preadipocytes      Arsenite     0.45               2 months     ↓ PPARγ mRNA\
                                                                                                                       ↓ Pioglitazone-stimulated adipocyte differentiation

   [@b53-ehp0114-000641]                    3T3-F442A preadipocytes       Arsenite     0.0017, 0.003      3 days       ↑ Expression of PPARγ and C/EBPα(genes with important roles in adipose determination)

  Glucose uptake in cultured cells                                                                                     

   [@b69-ehp0114-000641]                    BHK-21 cells                  Arsenite     3.75               2 hr         ↑ Basal glucose uptake; = insulin-stimulated glucose uptake\
                                                                                                                       = amino acid uptake

   [@b73-ehp0114-000641]                    BHK-21 cells                  Arsenite     15                 2 hr         ↑ Basal glucose uptake; ↑ glucose transporter translocation (reversible)

   [@b47-ehp0114-000641]                    BHK-21 cells                  Arsenite     4.5--7.5           2 hr         ↑ Basal glucose uptake (reversible when arsenite removed)\
                                                                                                                       Fast and reversible translocation of glucose receptor

   [@b30-ehp0114-000641]                    MDCK dog cells                Arsenite     37.5--75           1 hr         ↓ Basal glucose uptake, dose dependent

   [@b57-ehp0114-000641]                    BHK cells 3T3-L1 adipocytes   Arsenite     7.5--22.5          2 hr         ↑ Basal glucose uptake, dose dependent\
                                                                                                                       ↑ Glucose transporter translocation in both types of cells

   [@b40-ehp0114-000641]                    L6 rat muscle cells           Arsenite     7.5--112.5         0.5 hr       ↑ Basal glucose uptake, dose dependent but maximal with 37.5 ppm\
                                                                                                                       ↑ GLUT1 and GLUT4 in cell membrane, PI-3 kinase independent\
                                                                                                                       ↑ Insulin-stimulated glucose uptake

   [@b18-ehp0114-000641]                    Bovine adrenal cells          Arsenite     1.88--18.8         1 hr         ↑ Basal glucose uptake up to 7.5 ppm, then plateau\
                                                                                                                       PI-3 kinase independent, SAPK2/p38 partly involved

   [@b7-ehp0114-000641]                     3T3-L1 adipocytes             Arsenite     0.75--75           0.5 hr       ↑ Basal glucose uptake up to 37.5 ppm, then ↓\
                                                                                                                       ↓ Insulin-stimulated glucose uptake\
                                                                                                                       ↑ GLUT4 and GLUT1 translocation (but less than insulin)\
                                                                                                                       PI-3 kinase independent; no changes in IRβ, IRS-1, IRS-2\
                                                                                                                       No phosphorylation of PKB; PKC-λ/ζ and SAPK2/p38 involved

   [@b6-ehp0114-000641]                     3T3-L1 adipocytes             Arsenite     3.75--750          0.5 hr       ↑ Basal glucose uptake up to 37.5 ppm\
                                                                                                                       Dexamethasone ↓arsenite glucose uptake\
                                                                                                                       SAPK2/p38 involved

   [@b65-ehp0114-000641]                    3T3-L1 adipocytes             Arsenite     1.5, 7.5           4 hr         = basal glucose uptake at 1.50 ppm, ↓at 7.5 ppm, ↓insulin-stimulated

                                                                          MAs^III^O    0.08, 0.4                       = basal glucose uptake at 0.08 ppm, ↓at 0.4 ppm, ↓insulin-stimulated

                                                                          DMAs^III^I   0.15, 0.75                      = basal glucose uptake all doses, ↓insulin-stimulated

                                                                          Arsenate     7.5, 75                         ↑ basal glucose uptake at 7.5 ppm, ↓at 75 ppm, = insulin-stimulated

                                                                          MAs^V^       7.5, 75                         = basal glucose uptake all doses, ↓insulin-stimulated

                                                                          DMAs^V^      7.5, 75                         = basal and insulin-stimulated glucose uptake all doses,\
                                                                                                                       PI-3 kinase independent. No changes in IRβand IRS-2\
                                                                                                                       MAs^III^O and DAs^III^I, but not arsenite IRS-1, ↑phosphorylation of IRS-1\
                                                                                                                       Arsenite, MAs^III^O and DAs^III^I ↓phosphorylation of PKB/Akt\
                                                                                                                       Arsenite, MAs^III^O and DAs^III^I ↓GLUT4 translocation in insulin-treated cells

                                                                          Arsenite     0.4, 0.8, 1.5      24 hr        Dose-dependent ↓insulin-stimulated glucose uptake

                                                                          MAs^III^O    0.02, 0.04, 0.08                = insulin-stimulated glucose uptake at 0.02 ppm, ↓at 0.04 and 0.08

                                                                          DMAs^III^I   0.04, 0.08, 0.15                = insulin-stimulated glucose uptake all doses

  Miscellaneous experiments                                                                                            

   [@b55-ehp0114-000641]                    Rat hemidiaphragms            Arsenite     75                 1--3 hr      ↑ Basal glucose uptake in hemidiaphragms; ↑uptake with arsenate in fat pads = insulin stimulated glucose uptake in hemidiaphragm; ↓ uptake with arsenite in fat pad

                                            Epidydimal fat pads           Arsenate     75                              

   [@b15-ehp0114-000641]                    Epidydimal fat pads           Arsenite     0.75--7,500        3 hr         ↑ Basal glucose oxidation up to 7.5 ppm

   [@b10-ehp0114-000641]                    Rabbit kidney tubules         Arsenate     0.75--375          0.5 hr       ↓ Fluid, phosphate, and glucose absorption (lumen to bath)

   [@b22-ehp0114-000641]                    Rat jejunal segments          Arsenite     0.19--18.9         2 hr         ↓ Intestinal glucose transfer dose dependent (= arsenate \< 7.5 ppm)

                                                                          Arsenate     0.19--187.5                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1 ppm = 13.35 μM. Basal glucose uptake, glucose uptake in the absence of insulin. ↑, increase; ↓, decrease; = similar levels; BHK-21 cells, baby hamster kidney cells (contain predominantly GLUT1); C/EBPα, CCAAT/enhancer binding protein; DAs^III^I, iododimethylarsine; DMAs^V^, dimethylarsinic acid; GLUT, glucose transporter; IRβ: insulin receptor β; IRS, insulin receptor substrate; IUF-1, insulin upstream factor-1 (also called homeodomain transcription factor PDX1); MAs^III^O, methylarsine oxide; MAs^V^, monosodium methyl arsenate; MDCK dog cells, Madin-Darby canine kidney cells; ppm, part per million; PI-3 kinase, phosphatydilinositol-3 kinase; PKB, protein kinase B; PKC, protein kinase C; PPARγ, peroxisome proliferative-activated receptor γ; SAPK2, stress activator protein kinase 2 (also called p38 mitogen-activated protein kinase).

###### 

Experimental characteristics and ratio of glucose uptake in peripheral cell lines exposed to arsenite and insulin compared with insulin and arsenite alone.

                          Experiment characteristics   Ratio of glucose uptake vs.                         
  ----------------------- ---------------------------- ----------------------------- ------ ------- ------ ------
  [@b69-ehp0114-000641]   BHK-21 cells                 2                             3.75   100     0.94   0.91
  [@b40-ehp0114-000641]   L6 rat muscle cells          0.5                           37.5   100     1.42   1.21
  [@b7-ehp0114-000641]    3T3-L1 adipocytes            0.5                           37.5   100     0.57   1.33
  [@b65-ehp0114-000641]   3T3-L1 adipocytes            4                             1.50   1,000   0.60   0.55
  [@b65-ehp0114-000641]   3T3-L1 adipocytes            4                             7.49   1,000   0.20   0.33

BHK-21 cells, baby hamster kidney cells. For arsenite, 1 ppm = 13.35 μM.

###### 

*In vivo* studies of arsenic exposure and glucose metabolism.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                  Experimental Animal   *n*   Compound (route)                 Daily dose (ppm)   Duration   Outcomes and results (compared with controls)
  ----------------------- --------------------- ----- -------------------------------- ------------------ ---------- ---------------------------------------------------------------
  [@b24-ehp0114-000641]   Field mice            19    Methanearsonate (po in water)    1,000              30 days    ↓ Blood glucose, = fluid and food consumption

  [@b19-ehp0114-000641]   Rats                  12    Arsenite (ip)                    5--10              7 days     ↑ Glucose levels after glucose tolerance test, dose dependent

  [@b21-ehp0114-000641]   B6C3F~1~ mice         72    Arsenate (po in water)           0.025--2.5         28 days    ↓ Plasma glucose, = fluid and food consumption

  [@b1-ehp0114-000641]    Wistar rats           20    Arsenate (po in food)            5                  10 weeks   = Plasma glucose levels

  [@b13-ehp0114-000641]   Wistar rats           21    Arsenite (po in water)           17.75              1st week   Delayed glucose clearance after glucose tolerance test

                                                                                       up to 100          8th week   = Basal insulin levels *in vivo*

  [@b8-ehp0114-000641]    Bengal goats          12    Arsenite (po in capsule)         25                 12 weeks   ↑ Blood glucose at week 6 and ↑↑ at week 12

  [@b3-ehp0114-000641]    Fischer rats          480   Monomethylarsenic (po in food)   50--1,300          2 years    = Blood glucose levels up to 400 ppm, ↓with 1,300 ppm

  [@b44-ehp0114-000641]   Wistar rats           18    Arsenite (ip)                    5.55               21 days    ↓ Blood glucose (reversed with methionine)\
                                                                                                                     = Body, liver, kidney weight

  [@b45-ehp0114-000641]   Wistar rats           18    Arsenite (ip)                    5.55               30 days    ↓ Blood glucose (reversed with *N*-acetylcysteine)

  [@b46-ehp0114-000641]   Wistar rats           18    Arsenite (ip)                    5.55               30 days    ↓ Blood glucose (reversed with methionine)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ip, intraperitoneal; po, per oral; ↑, increase; ↓, decrease.

###### 

Epidemiologic studies of arsenic exposure and diabetes.

  Source                                                  Design   Country      Population                                           Diabetes diagnosis                           Cases/noncases   Men (%)   Age range (year)     Arsenic assessment             Levels, exposed vs. reference    RR of diabetes (95% CI)   Adjusted for
  ------------------------------------------------------- -------- ------------ ---------------------------------------------------- -------------------------------------------- ---------------- --------- -------------------- ------------------------------ -------------------------------- ------------------------- ----------------------------------
  General populations, high arsenic exposure                                                                                                                                                                                                                                                                                
   [@b28-ehp0114-000641]                                  CS       Taiwan       Survey of participants in high-arsenic area          OGTT or self-reported                        86/805           43        30--69               CEI village drinking water     \> 15 vs. 0 ppm-year             10.1 (1.30--77.9)         Age, sex, BMI, physical activity
   [@b59-ehp0114-000641]                                  RCO      Taiwan       Deaths in 1971--1994                                 Death certificate                            531 deaths       35        All ages             Living in HAA                  HAA vs. no HAA                   1.46 (1.28--1.67)         Age, sex
   [@b61-ehp0114-000641]                                  CO       Taiwan       Survey of participants in high-arsenic area          OGTT                                         41/405           50        Mean 47              CEI village drinking water     \> 17 vs. \< 17 ppm-year         2.10 (1.10--4.20)         Age, sex, BMI
   [@b66-ehp0114-000641]                                  CS       Taiwan       National Health Insurance Database                   ICD-9 250 ICD-9 A181                         27,543/678,791   43        25--65+              Living in HAA                  HAA vs. no HAA                   2.69 (2.65--2.73)         Age, sex
   [@b49-ehp0114-000641]                                  CS       Bangladesh   Survey participants in high- and low-arsenic areas   Self-reported symptoms + glucosuria + OGTT   46/971           59        30--60+              Living in HAA and keratosis    Keratosis vs. no keratosis       5.90 (2.90--11.6)         Age, sex, BMI
   [@b50-ehp0114-000641]                                  CS       Bangladesh   Survey participants in high-arsenic area             Glucosuria                                   263/1,332        61        30--60+              CEI village drinking water     \> 10 vs. 0 ppm-year             2.10 (1.10--4.20)         Age, sex
  Occupational populations, high arsenic exposure                                                                                                                                                                                                                                                                           
   [@b36-ehp0114-000641]                                  RCO      U.S.         Pesticide workers, Baltimore, MD                     Death certificate                            2 deaths         75        \< 20--40+ at hire   Job title                      Workers vs. general population   0.47 (0.12--1.88)         Age, sex, period
   [@b17-ehp0114-000641]                                  RCO      U.S.         Copper smelter workers, Washington State             Death certificate                            12 deaths        100       \< 20--69 at hire    Job title                      Workers vs. general population   0.85 (0.48--1.49)         Age
   [@b27-ehp0114-000641]                                  CS       Sweden       Copper smelter workers, other jobs                   Self-reported type 2 diabetes                4/85             100       Mean 57              Job title                      Workers vs. other workers        9.61 (0.53--173)          Crude
   [@b48-ehp0114-000641]                                  CC       Sweden       Copper smelter workers                               Death certificate, medical record            12/31            100       30--74 at death      Air levels                     \~ 5 vs. 0 mg/m^3^               3.30 (0.50--30.0)         Age
   [@b51-ehp0114-000641]                                  CC       Sweden       Deaths in glass industry area                        Death certificate                            240/2,216        100       45--75+              Job title                      Workers vs. other workers        1.40 (0.90--2.10)         Age
   [@b23-ehp0114-000641]                                  CS       Denmark      Taxidermists, wood workers, other jobs               HbA1c                                        5/59             87        Mean 37              Job title                      Workers vs. general population   4.43 (0.47--42.0)         Age
   [@b5-ehp0114-000641]                                   RCO      Italy        Glass industry workers                               Death certificate                            3 deaths         100       \< 40--65+           Job title                      Workers vs. general population   0.34 (0.09--0.88)         Age
   [@b35-ehp0114-000641]                                  RCO      U.S.         Copper smelter workers, Montana                      Death certificate                            54 deaths        100       \< 20--30+ at hire   Job title                      Workers vs. general population   0.83 (0.63--1.08)         Age
   [@b58-ehp0114-000641]                                  RCO      U.S.         Children \< 4 km of Copper smelter                   Death certificate                            16/3,116         58        \< 14                Years of residency             ≤10 vs. \< 1 year                1.60 (0.36--1.16)         Crude
  General populations, low to moderate arsenic exposure                                                                                                                                                                                                                                                                     
   Ward and Pim1984                                       CC       UK           Hospital based                                       NR                                           87/30            65        18--78               Plasma levels (NAA)            75th vs. 25th percentile         1.09 (0.79--1.49)         Crude
   [@b52-ehp0114-000641]                                  CC       Spain        Hospital based                                       NR                                           38/49            39        NR                   Urinary levels (AAS)           75th vs. 25th percentile         0.87 (0.50--1.53)         Crude
   [@b29-ehp0114-000641]                                  CO       U.S.         Mormons                                              Death certificate                            55/4,003         52        \< 50--80+           CEI community drinking water   \> 4 vs. \< 1 ppm-year           0.65 (0.34--1.24)         Age, sex
   [@b78-ehp0114-000641]                                  CC       U.S.         Survey participants with private wells               Self-reported                                67/1118          NR        Mean 62              Subject drinking water         \> 10 vs. \< 2 ppb               1.02 (0.49--2.15)         Age, sex, BMI, smoking

Abbreviations: AAS, atomic absorption spectrometry; BMI, body mass index; CC, case--control; CEI, cumulative exposure index: ∑ arsenic levels in drinking water*~i~* *×* time of exposure*~i~* (*i* indicates specific village); CO, cohort; CS, cross-sectional; HAA, high-arsenic area; HbA1c, hemoglobin A1c; ICD-9, *International Classification of Diseases, Ninth revision*; NAA, neutron activation analysis; NR, not reported; OGTT, oral glucose tolerance test, criteria for a positive test based on the WHO criteria; RCO, retrospective cohort; RR, relative risk.

###### 

Criteria for evaluating the design and data analysis of epidemiologic studies on arsenic and diabetes.[a](#tfn6-ehp0114-000641){ref-type="table-fn"}

                                                                                                                                 Taiwan and Bangladesh   Occupational populations   Other populations                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------ ----------------------- -------------------------- ------------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  All studies (n = 19)                                                                                                                                                                                                                                                                            
   Diabetes diagnosis based on fasting glucose levels or oral glucose tolerance tests                                            Y                       N                          Y                   N     N     N     N     N     N     N     N     N     N     N     N     N     N     N     N
   Exposure assessed at the individual level                                                                                     N                       N                          N                   N     N     N     N     N     N     Y     N     N     N     N     Y     Y     Y     N     Y
   Exposure assessed using a biomarker of exposure                                                                               N                       N                          N                   N     N     N     N     N     N     N     N     N     N     N     N     Y     Y     N     N
   Control for established diabetes risk factors in addition to age                                                              Y                       N                          Y                   N     N     N     Y     N     N     N     N     N     N     N     N     N     N     N     Y
  Case--control and cross-sectional studies (*n* = 11)                                                                                                                                                                                                                                            
   Response rate among noncases at least 70%[b](#tfn7-ehp0114-000641){ref-type="table-fn"}                                       Y                       ---                        ---                 Y     N     Y     ---   ---   N     ---   ---   N     ---   ---   ---   N     N     ---   N
   Noncases would have been cases if they had developed diabetes                                                                 N                       ---                        ---                 N     N     N     ---   ---   N     N     N     Y     ---   ---   ---   N     N     ---   N
   Data collected in a similar manner for all participants                                                                       Y                       ---                        ---                 Y     N     N     ---   ---   N     Y     Y     Y     ---   ---   ---   N     N     ---   Y
   Cases interviewed within 6 months of diagnosis                                                                                N                       ---                        ---                 N     N     N     ---   ---   N     N     N     N     ---   ---   ---   N     N     ---   N
   Interviewer blinded with respect to the case status of the person interviewed[c](#tfn8-ehp0114-000641){ref-type="table-fn"}   Y                       ---                        ---                 ---   N     N     ---   ---   N     N     N     Y     ---   ---   ---   N     N     ---   Y
   Time period during which all participants were interviewed was the same[c](#tfn8-ehp0114-000641){ref-type="table-fn"}         Y                       ---                        ---                 ---   N     N     ---   ---   N     Y     Y     N     ---   ---   ---   N     N     ---   Y
   Same exclusion criteria applied to all participants                                                                           Y                       ---                        ---                 Y     N     N     ---   ---   N     Y     N     N     ---   ---   ---   N     N     ---   Y
  Cohort studies (*n* = 8)                                                                                                                                                                                                                                                                        
   Loss to follow-up was independent of exposure                                                                                 ---                     N                          Y                   ---   ---   ---   N     N     ---   ---   ---   ---   N     N     N     ---   ---   Y     ---
   Intensity of search of disease independent of exposure status                                                                 ---                     N                          Y                   ---   ---   ---   N     N     ---   ---   ---   ---   N     N     N     ---   ---   Y     ---

Abbreviations: ---, not applicable; N, no; Y, yes.

Criteria modified from [@b33-ehp0114-000641].

Not applicable to two case--control studies based only on deaths ([@b48-ehp0114-000641]; [@b51-ehp0114-000641]).

Not applicable to the study using the National Health Insurance Database from Taiwan ([@b66-ehp0114-000641]).
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